Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
Fate Therapeutics
University of Maryland, Baltimore
Icahn School of Medicine at Mount Sinai
US Oncology Research
International Myeloma Foundation
Hellenic Society of Hematology
Fate Therapeutics
Singapore General Hospital
Hellenic Society of Hematology
Tel-Aviv Sourasky Medical Center
Assistance Publique - Hôpitaux de Paris
National University Hospital, Singapore
Vejle Hospital